申请人:Cerus Corporation
公开号:EP1584622A2
公开(公告)日:2005-10-12
Psoralen compounds are synthesized which have substitutions on the 4, 4', 5' and 8 positions of the psoralen, which permit enhanced binding to nucleic acid of pathogens.
Higher psoralen binding levels and lower mutagenicity are described, resulting in safer, more efficient, and reliable inactivation of pathogens in blood products. The invention contemplates inactivation methods using the new psoralens which do not compromise the function of blood products for transfusion.
所合成的补骨脂素化合物在补骨脂素的 4、4'、5'和 8 位上具有取代位,可增强与病原体核酸的结合。
据介绍,补骨脂素的结合水平更高,诱变性更低,从而能更安全、更有效、更可靠地灭活血液制品中的病原体。本发明考虑使用新的补骨脂素灭活方法,这种方法不会损害输血产品的功能。